Peptide Skincare & BeautySkin science and ingredient guides

Ingredient or product comparison

GHK-Cu vs Minoxidil and Finasteride for TE Recovery

Most patients encountering telogen effluvium are prescribed minoxidil (Rogaine) or finasteride (Propecia). Neither of which addresses the root cause of TE. Minoxidil is a vasodilator that increases blood flow to follicles but does not influence the hormonal or

This source-based comparison does not add ratings or recommend a winner.

  • Most patients encountering telogen effluvium are prescribed minoxidil (Rogaine) or finasteride (Propecia). Neither of which addresses the root cause of TE. Minoxidil is a vasodilator that increases blood flow to follicles but does not influence the hormonal or metabolic signals that triggered telogen entry. Finasteride inhibits 5-alpha reductase (blocking DHT conversion) and is effective for androgenetic alopecia but irrelevant for TE caused by stress, thyroid dysfunction, or nutritional deficiency.
  • GHK-Cu studied in telogen effluvium contexts works through a fundamentally different pathway. It does not dilate vessels or block hormones. It directly stimulates dermal papilla cells to resume anagen signaling. This makes GHK-Cu particularly suited for acute TE (postpartum, post-surgery, telogen after fever or crash dieting) where the follicles are intact but metabolically suppressed.
  • GHK-Cu
  • Dermal papilla cell proliferation via TGF-beta and VEGF upregulation
  • High. Directly addresses follicle dormancy at cellular level
  • 8–12 weeks visible regrowth
  • Preclinical (in vitro validated, limited human RCTs)
  • Minoxidil 5%
  • Vasodilation increases nutrient delivery to follicles
  • Moderate. Supportive but does not reverse metabolic suppression
  • 12–16 weeks visible regrowth
  • FDA-approved for androgenetic alopecia (off-label for TE)
  • Finasteride 1mg
  • Inhibits 5-alpha reductase, reducing DHT-mediated miniaturization
  • Low. Irrelevant unless TE is compounded by androgenetic alopecia
  • 16–24 weeks visible regrowth
  • FDA-approved for androgenetic alopecia only
  • Platelet-Rich Plasma (PRP)
  • Growth factor delivery from autologous platelets
  • High. Similar growth factor signaling to GHK-Cu
  • Established clinical use (dozens of RCTs)
  • Professional Assessment
  • GHK-Cu and PRP target the same biological mechanisms but via different delivery routes. GHK-Cu offers peptide precision without the procedural cost or discomfort of PRP injections. Minoxidil can be stacked with GHK-Cu. Finasteride is unnecessary unless androgenetic alopecia coexists.